Home › Cases › Not Improving at Day Five
Hospital-Acquired Pneumonia
Not Improving at Day Five
6 questions
Question 1 · The review
Correct answer: Seek microbiology advice rather than escalating empirically, and look for a complication
Why
Not improving, or MDR organism: microbiology advice, not empirical escalation.
Empirical escalation at day 5 is the reflex the pathway names specifically. It treats the antibiotic as the only variable when the more likely explanations are a complication — empyema, a parapneumonic effusion, an abscess — or that it was never HAP.
"Mixed flora" is a non-result and does not license a narrower or a broader choice.
Key point
Failure at day 5 means microbiology advice, not the next antibiotic up.
Question 2 · The complication
Correct answer: Ultrasound and respiratory referral — suspected empyema or parapneumonic effusion
Why
Suspected empyema or parapneumonic effusion — ultrasound and respiratory referral. Ultrasound tells you whether it is septated and where to put a needle; a blind ward tap in a patient like this is how you get a pneumothorax on top of a pneumonia.
CT has a role once the referral is made and is not the reason to delay making it.
Key point
New effusion in a non-improving pneumonia → ultrasound and respiratory, not a blind tap.
Question 3 · The marker
Correct answer: CRP or procalcitonin at day 3 to 4 if worried about failure
Why
CRP or procalcitonin at day 3–4 if worried about failure. It is a question asked at a specific point for a specific reason, not a daily habit and not an entry gate.
Treating a normal CRP as permission to stop, or a raised one as a reason to continue, replaces the clinical assessment the pathway actually asks for — review at 5 days and consider stopping if clinically stable.
Key point
CRP or procalcitonin at day 3–4, if worried. Not daily, and not a gate on starting.
Question 4 · Oxygen
Correct answer: Critical care review, and consider high-flow nasal oxygen
Why
Rising oxygen requirement or type 1 failure — critical care review; consider HFNO.
NIV is for type 2 failure, and starting it on a ward for type 1 pneumonia delays the review he needs. A reservoir mask and a plan to look again in the morning is the decision that shows up at the mortality meeting.
Key point
Type 1 failure or a rising requirement → critical care review, consider HFNO.
Question 5 · MRSA
Correct answer: Vancomycin or teicoplanin
Why
MRSA suspected or confirmed: add vancomycin or teicoplanin. Linezolid only on specialist advice.
The lung penetration argument for linezolid is real and is exactly why it is a specialist decision rather than a ward one — it has its own toxicities and resistance consequences.
Piperacillin-tazobactam does not cover MRSA.
Key point
MRSA → vancomycin or teicoplanin. Linezolid only on specialist advice.
Question 6 · One that is almost never right
Correct answer: Only if nothing else is suitable — per the MHRA warning of January 2024
Why
Levofloxacin only if nothing else is suitable — MHRA, January 2024. The restriction follows disabling and potentially irreversible adverse effects: tendon, musculoskeletal, neurological and psychiatric.
It is not an absolute contraindication by age, and "it would be convenient" is not the bar the MHRA set. If it genuinely is the only option, that is a decision made with microbiology and documented.
Key point
Fluoroquinolones are a last resort — MHRA Jan 2024, not a convenience choice.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.